METHODS AND COMPOSITIONS COMPRISING MHC CLASS PEPTIDES
The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of Table 1. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of Table 1. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 25. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
YEE CASSIAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-04-17, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
US2024024438 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003626261 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003626261 | ||
| 003 | DE-627 | ||
| 005 | 20240426160234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240419s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003626261 | ||
| 035 | |a (EPA)US2024024438 | ||
| 035 | |a (EPA)81708082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a YEE CASSIAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METHODS AND COMPOSITIONS COMPRISING MHC CLASS PEPTIDES |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-04-17, Last updated: 2024-04-26 | ||
| 520 | |a The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of Table 1. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of Table 1. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure. | ||
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a PAN KE |e verfasserin |4 aut | |
| 700 | 0 | |a CHIU YULUN |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 25. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81708082/publication/US2024024438A1?q=US2024024438 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 01 | ||